E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Symptoms and general pathology [C23] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10014542 |
E.1.2 | Term | Emesis |
E.1.2 | System Organ Class | 100000017043 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Objectives: The primary objective is to test if olanzapine 10 mg is effective in patients with advanced cancer not receiving chemotherapy or irradiation. Hypotheses: Administration of olanzapine will result in a change in nausea score from baseline to 24 hours later exceeding 30%. In patients included because of vomiting only (nausea score less than moderate), the primary parameter will be change in number of emetic episodes from baseline to 24 hours later.
|
|
E.2.2 | Secondary objectives of the trial |
1. Two-item nausea score and CAT (computer adaptive testing)-score recorded on the ext. EORTC QLQ-C15-PAL at baseline, 24 hours and after 7 days. 2. Number of emetic episodes (vomit/dry retch) in the first 24 hours after administration of study medication. 3. Time to first emetic episode. 4. Nausea score measured daily for 7 days following administration of study medication 5. Number of emetic episodes measured daily for 7 days following the administration of study medication. 6. Tolerability of olanzapine 10 mg for 5 consecutive days. 7. Parameters indicative of efficacy: appetite, fatigue, pain, emotional function and overall quality of life. 8. Use of rescue anti-emetics.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Advanced cancer 2. Age ≥ 18 years 3. One or both of the following: 3.1. Nausea at least ‘moderate’ on the baseline diary 3.2. At least 1 emetic episode within the last 24 hours (recorded on the baseline diary) 4. Ability to read and understand the forms required for the study 5. Life-expectancy more than 2 weeks
|
|
E.4 | Principal exclusion criteria |
1. Contraindications for olanzapine including allergic reaction, phenylketonuria and diagnosed glaucoma 2. Cardiovascular disease, other than hypertension 3. Parkinson’s disease 4. Dementia 5. Epilepsy 6. Symptoms of increased intracranial pressure or cerebral metastasis. If this is suspected, a normal MR scan of the cerebrum are needed before inclusion 8. Radiologic confirmed ileus, or clinical suspicion evaluated by the study Investigator 9. Cognitive impairment or language barrier that makes the patient unable to complete the questionnaires 10. Surgery to the brain or abdomen within the last 2 weeks or exposure to general anesthesia within the last 4 days. 11. Chemotherapy within the last 2 weeks 12: Radiation therapy targeting the brain or abdomen within the last 2 weeks 12. Pregnancy 13. Reversible causes of nausea/vomiting: e.g. Hypercalcemia, uremia , newly commenced/changed opioid-therapy (within 7 days), other medication with emetic potential |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Nauseascore 2. Number of emetic episodes |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Recorded at baseline and 24 hours following first dose
|
|
E.5.2 | Secondary end point(s) |
1. Two-item nausea score and CAT (computer adaptive testing)-score. 2. Number of emetic episodes (vomit/dry retch) in the first 24 hours after administration of study medication. 3. Time to first emetic episode. 4. Nausea score 5. Number of emetic episodes. 6. Tolerability of olanzapine 10 mg for 5 consecutive days. 7. Parameters indicative of efficacy: appetite, fatigue, pain, emotional function and overall quality of life. 8. Use of rescue anti-emetics.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Baseline and study day 2 + baseline and daily study day 1-7 2. Baseline and study day 2 3. Daily study day 1-7. 4. Baseline and daily study day 1-7 5. Baseling and study day1-7 6: Baseline, study day 2 and 7. 7: Baseline and study day 7 8. Baseline + daily staudy day 1-7. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | |